Integra LifeSciences has earned CE mark approval in Europe to market a device used to help patients with diabetes manage their chronic wounds. The Integra Flowable Wound Matrix system, which works by filling deep soft tissue or tunneling wounds, could help reduce the risk of amputation in patients with diabetes.

Full Story:
RTT News

Related Summaries